Vyne Therapeutics Inc.
13F holders, Q3 2024 (September 30)At the end of Q3 2024, 32 institutions reported holding Vyne Therapeutics Inc. in their 13F filings, up 2 from Q2 2024. 2 opened new positions and 0 sold out. The largest holders were Eventide Asset Management, LLC ($3.1M), Cormorant Asset Management, LP ($2.6M) and Citadel Advisors ($2.2M). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Vyne Therapeutics Inc.
- CUSIP
- 92941V308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $34K |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 42,077 shares bought and 694,196 shares sold, net −652,119 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 32 holders
| Eventide Asset Management, LLC | 0.05% | No change | 1,394,336 | $3.1M |
| Cormorant Asset Management, LP | 0.14% | No change | 1,394,336 | $2.6M |
| Citadel Advisors | 0.00% | Reduce -1.9% | 1,187,413 | $2.2M |
| DSC Advisors, L.P. | 11.93% | No change | 696,465 | $1.3M |
| Palo Alto Investors LP | 0.11% | No change | 445,434 | $837K |
| Vanguard Group Inc. | 0.00% | No change | 443,518 | $834K |
| Exome Asset Management LLC | 0.45% | No change | 353,434 | $664K |
| AlphaCentric Advisors LLC | 0.38% | Reduce -13.5% | 268,485 | $505K |
| Parkman Healthcare Partners LLC | 0.05% | Reduce -41.2% | 202,973 | $382K |
| Schonfeld Strategic Advisors LLC | 0.00% | Reduce -22.0% | 168,600 | $317K |
| ADAR1 Capital Management, LLC | 0.05% | Reduce -10.7% | 152,865 | $287K |
| Geode Capital Management, LLC | 0.00% | Reduce -0.8% | 134,590 | $253K |
| Renaissance Technologies | 0.00% | Add +37.3% | 86,643 | $163K |
| BlackRock, Inc. | 0.00% | — | 83,069 | $156K |
| Silverarc Capital Management, LLC | 0.03% | Reduce -83.6% | 76,784 | $144K |
| Prelude Capital Management, LLC | 0.01% | Add +0.2% | 65,147 | $122K |
| Susquehanna International Group, LLP | 0.00% | Add +0.1% | 60,356 | $113K |
| Northern Trust Corp. | 0.00% | Reduce -1.0% | 37,290 | $70K |
| Commonwealth Equity Services, LLC | 0.00% | New | 18,298 | $34K |
| Lynx1 Capital Management LP | 0.01% | No change | 16,194 | $30K |
| State Street Corp. | 0.00% | No change | 15,765 | $30K |
| Royal Bank of Canada | 0.00% | Reduce -45.2% | 2,440 | $5K |
| Bank of America Corp. | 0.00% | Reduce -1.2% | 2,278 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -34.7% | 2,209 | $4K |
| Morgan Stanley | 0.00% | No change | 1,799 | $3K |
| Mb, Levis & Associates, LLC | 0.00% | No change | 1,041 | $2K |
| Centerpoint Advisors, LLC | 0.00% | No change | 350 | $1K |
| Russell Investments Group, Ltd. | 0.00% | No change | 187 | $351 |
| JPMorgan Chase & Co. | 0.00% | Add +0.6% | 177 | $332 |
| Barclays PLC | 0.00% | New | 100 | $188 |
| Wells Fargo & Company | 0.00% | No change | 65 | $122 |
| UBS Group AG | 0.00% | Reduce -99.9% | 14 | $26 |
"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.